



12-08-04

1647 \$

R/W

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ashkenazi, et al. Docket No.: 39780-1618P2C14  
Serial No.: 09/903,562 Group Art Unit: 1647  
Filing Date: July 11, 2001 Examiner: Deberry, Regina M.  
For: **Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same**

EXPRESS MAIL LABEL NO.: EL 993 687 354 USDATE MAILED: December 6, 2004

**SUPPLEMENTAL**  
**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97**

**MS: AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication, except U.S. patents and patent application publications (1276 OG 55), is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §§ 1.97-1.98.

In addition, each reference listed and denoted by an asterisk (\*) have been cited in a related patent application, US Serial No. 09/904,532 (claiming PRO 224 polypeptide); Our Ref. No. 39780-1618P2C13 and/or US Serial No. 09/906,722 (claiming PRO 224 nucleic acid); Our Ref. No. 39780-1618P2C61. A copy of each reference is provided herewith. Applicants submit these documents to ensure that all references are of record and considered in all related applications. Applicants respectfully request the Examiner to acknowledge consideration of the currently submitted references by initialing and returning form PTO-1449 in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)

-- OR --

☐ (2) It is being filed within 3 months of entry of a national stage

-- OR --

- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-1618P2C14).

Respectfully submitted,

Dated: December 6, 2004

By: Daphne Reddy  
Daphne Reddy  
Reg. No. 53,507

**HELLER EHRMAN WHITE & MCAULIFFE, LLP**  
Customer No. 35489/09157  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

<b>INFORMATION DISCLOSURE STATEMENT</b> <b>PTO-1449</b>			<b>ATTY. DOCKET NO.:</b>		<b>SERIAL NO.:</b>	
			39780-1618P2C14		09/903,562	
			<b>APPLICANT : Ashkenazi, et al.</b>			
			<b>FILING DATE: 07/11/01</b>		<b>GROUP: 1647</b>	
<b>U.S. PATENT DOCUMENTS</b>						
<b>EXAMINER'S INITIALS</b>	<b>PATENT NO.</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE</b>
	* 6,284,485	09//04/2001	Boyle et al.	435	69.1	
	* 6,590,075	07/08/2003	Ruben et al.	530	350	
	* 5,194,596	03/16/1993	Tischer et al.	530	399	
<b>FOREIGN PATENT DOCUMENTS</b>						
<b>EXAMINER'S INITIALS</b>	<b>PATENT NO.</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION</b>
						<b>YES</b>
						<input type="checkbox"/> YES <input type="checkbox"/> NO
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	42 human EST's putatively encoding proteins having similarity with lipoprotein receptors disclosed before 17.09.97; Host: NCBI, Database: Genbank.					
	500 human EST's putatively encoding secreted or transmembrane proteins disclosed before 28.10.97; Host: NCBI, Database: Genbank.					
	* Barber et al., "The Receptor for Yolk Lipoprotein Deposition in the Chicken Oocyte", The Journal of Bio. Chem., Vol. 266, No. 28, pp. 18761-18770, 1991.					
	* Depenbrock et al, "Preclinical Activity of Trans-indazolium [Tetrachlorobisindazoleruthenate (III)] (NSC 666158; IndCR; KP1019) Against Tumor Colony-forming Units and Haematopoietic Progenitor Cells", European Journal of Cancer, Vol. 33, No. 14, pp. 2404-2410, 1997.					
	* Hanauske et al, "Adenocarcinoma of unknown primary retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system", Investigational New Drugs, Vol. 13, pp. 43-49, 1995.					
	* Huang et al, "NMR Solution Structure of Complement-like Repeat CR8 form the Low Density Lipoprotein Receptor-related Protein", The Jour. of Biol. Chem., Vol. 274, No. 20, pp. 14130-14136, 1999.					
	* Kornblith et al, "In Vitro Responses of Ovarian Cancers to Platinums and Taxanes", Anticancer Research, Vol. 23, pp. 543-548, 2003.					
	* Lawrence et al. "Comparison of DX-8951f and topotecan effects on tumor colony formation form freshly explanted adult and pediatric human tumor cells", Anti-Cancer Drugs, Vol. 10, pp. 655-661, 1999.					
	Lestralval and Fruchart, "Lipoprotein Receptors", Cell. Mol. Biol., Vol. 40, No. 4, pp. 461-481, 1994.					
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.